Table 2 Baseline comparison for primary and secondary efficacy endpoints at Day 29 (ITT population)

Primary FRI endpoints

 Untrimmed siVaw at TLC^a

  Geometric mean, mL/L

2.05

2.00

  Ratio to baseline (95% CI)

1.72 (1.38, 2.13)****

1.53 (1.28, 1.83)****

 Untrimmed siRaw at TLC^a

  Geometric mean, kPa·s

0.21

0.20

  Ratio to baseline (95% CI)

0.50 (0.39, 0.63)****

0.52 (0.40, 0.67)****

Secondary endpoints

 FRI

  iVaw at TLC^a

   Geometric mean, mL

2.74

2.71

   Ratio to baseline (95% CI)

1.70 (1.37, 2.11)****

1.51 (1.26, 1.80)****

  iRaw at TLC^a

   Geometric mean, kPa·s/L

0.18

0.16

   Ratio to baseline (95% CI)

0.50 (0.40, 0.63)****

0.52 (0.40, 0.68)****

 Spirometry

  Post-dose FEV₁^b

   Mean change from baseline (95% CI)_, mL

346 (182, 509)***

273 (140, 405)***

 Body plethysmography

  FRC^c

   Mean change from baseline (95% CI), mL

–280 (–770, 210)

–500 (–810, –180)**

Other endpoints

 FVC^b

  Mean change from baseline (95% CI), mL

422 (180, 663)**

302 (119, 485)**

 FEF_25–75^b

  Mean change from baseline (95% CI), mL/s

263 (17, 509)*

83 (–153, 319)